Medtronic/Kyphon merger gets early US OK:
This article was originally published in Clinica
Executive Summary
Medtronic's proposed $3.9bn acquisition of balloon kyphoplasty specialist Kyphon has received the go-ahead from US regulators, who agreed to an early termination of the waiting period required under the US antitrust act. The transaction still requires regulatory approval from several other jurisdictions, as well as approval from Kyphon's shareholders, who will vote in a special meeting set for October 16.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.